ArticleToxicology research2025
lncRNA PART1 improves sevoflurane-induced impairments in learning and cognitive function by regulating miR-16-5p expression and reducing neuroinflammation.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of airway stress response and respiratory complications in adults undergoing general anesthesia with sevoflurane plus mivacurium chloride and positive pressure ventilation via laryngeal mask.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sevoflurane is a commonly utilized inhalational anesthetic in surgical settings. Nevertheless, sevoflurane has been demonstrated to possess neurotoxic properties. The objective was to examine the neuroprotective function of long non-coding RNA prostate androgen-regulated transcript 1 (PART1) in sevoflurane-induced neurotoxicity and to elucidate its potential mechanism. The level of PART1 was quantified by RT-qPCR. The proliferation and apoptosis of HT22 cells were evaluated through CCK-8 assay and flow cytometry, respectively. To assess the protein level of IL-6, IL-1β, and TNF-α, ELISA was conducted. The levels of malondialdehyde, nitrite, and reduced glutathione along with the activity of superoxide dismutase were determined to evaluate oxidative stress. Verification of the targeting relationship between miR-16-5p and PART1 was performed using the dual-luciferase reporter assay. The Morris water maze test was used to assess the impact of PART1 on sevoflurane-induced learning and cognitive function in rats. PART1 levels were decreased in sevoflurane-treated HT22 cells and rats. PART1 suppressed sevoflurane-induced apoptosis and attenuated its inhibitory effect on cell proliferation. PART1 mitigated sevoflurane-induced inflammatory response and oxidative stress in HT22 cells through the regulation of miR-16-5p. PART1 suppressed oxidative damage and inflammatory response leading to improvement of learning and cognitive function in rats subjected to sevoflurane exposure. PART1 has the potential to regulate the sevoflurane-induced inflammatory response and oxidative stress via miR-16-5p, which in turn improves learning and cognitive function. Consequently, PART1 may be a promising therapeutic target for sevoflurane-induced neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.